Suspected Adult-Onset Congenital Myasthenic Syndrome Associated With a Heterozygous CHRND Variant in a Patient With Seropositive Rheumatoid Arthritis: A Case Report
Background:Congenital myasthenic syndrome (CMS) is a clinically and genetically heterogeneous disorder of neuromuscular transmission, with more than 35 associated genes.Although CMS typically presents at birth or in early childhood, adult-onset forms are increasingly recognized and frequently mimic seronegative autoimmune myasthenia gravis, causing diagnostic delay.Its prevalence (2.8-14.8 per million) is probably underestimated, particularly for mild, late-onset, or atypical phenotypes. Case Report:A 42-year-old man with well-controlled seropositive rheumatoid arthritis presented with progressive fatigue, fluctuating proximal weakness (Medical Research Council grade 4/5 with fatigability), bilateral ptosis, and intermittent diplopia.Nerve conduction studies, repetitive nerve stimulation, and electromyography were normal, and a comprehensive autoimmune and myositis antibody panel was negative, prompting genetic testing.Whole-exome and whole-genome sequencing identified a heterozygous pathogenic CHRND variant; additional variants of uncertain or unrelated significance were also detected.Because CHRND-related CMS is classically autosomal recessive and single-fiber electromyography was not performed, a single heterozygous variant cannot be regarded as confirmatory, and the diagnosis is considered suspected rather than definitive.Pyridostigmine produced clinically meaningful improvement-reduced ptosis, resolved diplopia, and improved endurancethat was sustained at the 6-week follow-up. Conclusions:CMS should be considered in adults with fatigable weakness and atypical neuromuscular features once autoimmune causes are excluded; however, a single heterozygous variant without confirmatory electrophysiology limits diagnostic certainty.To our knowledge, this is the first report of a suspected CHRND-associated adultonset CMS with seropositive rheumatoid arthritis.Broad genetic testing is valuable when phenotype and serology diverge, but results must be interpreted cautiously alongside electrophysiological confirmation before a definitive diagnosis.
Authors
- Hanan Almalki (ORCID: https://orcid.org/0000-0002-7912-0245)
- Faisal Saud Alhudaithi
- Khaled Abdulwahab Amer
Institutions
- Asir Central Hospital (SA)
- King Khalid University (SA)
Publication Details
- Journal
- American Journal of Case Reports
- Published
- 2026-06-08
- DOI
- https://doi.org/10.12659/ajcr.952887
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00